✦ LIBER ✦

1057 PLASMA BIOMARKERS AS PREDICTORS OF OUTCOME IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: RESULTS FROM THE RANDOMIZED PHASE III SHARP TRIAL

✍ Scribed by Llovet, J.; Pena, C.; Shan, M.; Lathia, C.; Bruix, J.

Book ID: 123156817
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 51 KB
Volume: 50
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(09)61059-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Plasma Biomarkers as Predictors of Outco

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

✍ Llovet, J. M.; Pena, C. E. A.; Lathia, C. D.; Shan, M.; Meinhardt, G.; Bruix, J. 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 596 KB

6519 Efficacy and safety of sorafenib in

6519 Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials

✍ Llovet, J.; Cheng, A.; Qin, S.; Shan, M.; Nadel, A.; Burock, K.; Forner, A.; Zou 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Brivanib in Patients With Advanced Hepat

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

✍ Llovet, J. M.; Decaens, T.; Raoul, J.-L.; Boucher, E.; Kudo, M.; Chang, C.; Kang 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 229 KB

7134 Evaluation of quality of life in pa

7134 Evaluation of quality of life in patients with advanced renal cell carcinoma treated with temsirolimus vs interferon-alfa: results from a phase III randomized trial

✍ Yang, S.; Hudes, G.; deSouza, P.; Alemao, E.; Strahs, A.; Purvis, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

O4 Tivozanib hydrochloride versus sorafe

O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

✍ Motzer, R.; Nosov, D.; Eisen, T.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Harza, M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

6621 Effect of macroscopic vascular inva

6621 Effect of macroscopic vascular invasion (MVI), extrahepatic spread (EHS), and ECOG performance status (ECOG PS) on outcome in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib: analysis of two phase III, randomized, double-blind trials

✍ Raoul, J.; Cheng, A.L.; Kang, Y.K.; Tsao, C.J.; Zou, J.; Nadel, A.; Burock, K.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB